2026-07-21T07:57:56Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/181632024-11-28T15:03:37Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16960col_20.500.12105_16961
Repisalud author Eguiluz-Gracia, Ibon author Palomares, Francisca author Salas, Maria author Testera-Montes, Almudena author Ariza, Adriana author Davila, Ignacio author Bartra, Joan author Mayorga, Cristobalina author Torres, Maria Jose author Rondon, Carmen authoraffiliation [Eguiluz-Gracia,I; Salas,M; Testera-Montes,A; Mayorga,C, Torres,MJ; Rondon,C] Allergy Unit, Hospital Regional Universitario de Malaga, Malaga, Spain. [Eguiluz-Gracia,I; Palomares,F; Salas,M; Ariza,A; Mayorga,C, Torres,MJ; Rondon,C] Allergy Research Group, Instituto de Investigación Biomedica de Malaga-IBIMA and ARADyAL, Malaga, Spain. [Testera-Montes,A; Torres,MJ] Department of Medicine and Dermatology, Universidad de Malaga, Malaga, Spain. [Davila,I] Allergy Department, University Hospital of Salamanca, Salamanca, Spain. [Davila,I] Allergy Research Group, Institute for Biomedical Research of Salamanca (IBSAL) and ARADyAL, Salamanca, Spain. [Davila,I] Department of Biomedical and Diagnostic Sciences, Universidad de Salamanca, Salamanca, Spain. [Bartra,J] Allergy Section, Pulmonology, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain. [Bartra,J] Clinical & Experimental Respiratory Immunoallergy (IRCE), Instituto de Investigaciones Biomedicas Pi I Sunyer (IDIBAPS)-ARADyAL, Barcelona, Spain. [Mayorga,C, Torres,MJ] Laboratory for Nanostructures for the Diagnosis and Treatment of Allergic Diseases, Andalusian Center for Nanomedicine and Biotechnology (BIONAND), Malaga, Spain. 2024-02-12T19:48:09Z 2024-02-12T19:48:09Z 2020-11-26 10.3390/jcm9123827 2077-0383 Journal of Clinical Medicine http://hdl.handle.net/10668/3833 33255966 http://hdl.handle.net/20.500.12105/18163 House dust mites (HDMs) are the allergenic sources most frequently involved in airway allergy. Nevertheless, not every sensitized patient develops respiratory symptoms upon exposure to HDM, and there is a clinical need to differentiate allergic asthmatics (AAs) from atopic non-allergic asthmatics with HDM sensitization. This differentiation sometimes requires in vivo provocations like the bronchial allergen challenge (BAC). Interestingly, recent data demonstrate that non-atopic patients with asthma can also develop positive BAC results. This novel phenotype has been termed local allergic asthma (LAA). The interest in identifying the allergic triggers of asthma resides in the possibility of administering allergen immunotherapy (AIT). AIT is a disease-modifying intervention, the clinical benefit of which persists after therapy discontinuation. Recently, new modalities of sublingual tablets of HDM immunotherapy registered as pharmaceutical products (HDM-SLIT tablets) have become commercially available. HDM-SLIT tablets have demonstrated a robust effect over critical asthma parameters (dose of inhaled corticosteroids, exacerbations, and safety), thus being recommended by international guidelines for patients with HDM-driven AA. In this review, we will summarize the current knowledge on the phenotype and endotype of HDM-driven AA, and LAA, address the difficulties for BAC implementation in the clinic, and discuss the effects of AIT in AA and LAA. eng House dust mites Allergic asthma Local allergic asthma Bronchial allergen challenge Sublingual allergen immunotherapy Antígenos dermatofagoides Pyroglyphidae Hipersensibilidad respiratoria Pruebas de provocación bronquial Inmunoterapia sublingual Precision Medicine in House Dust Mite-Driven Allergic Asthma review article